Preoperative radiotherapy combined with intraoperative radiotherapy improve results of total mesorectal excision in patients with T3 rectal cancer

被引:19
作者
Pacelli, F
Di Giorgio, A
Papa, V
Tortorelli, AP
Covino, M
Ratto, C
Bossola, M
Valentini, V
Sofo, L
Miccichè, F
Gambacorta, MA
Doglietto, GB
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Digest Surg Unit, Dept Surg Sci, I-00135 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Sch Med, Dept Emergency Med, I-00135 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Sch Med, Dept Radiat Therapy, I-00135 Rome, Italy
关键词
D O I
10.1007/s10350-003-0028-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: The survival advantage of preoperative radiotherapy in patients with rectal cancer is still a matter of debate, because its incremental benefit in the total mesorectal excision setting is unclear. This study was designed to evaluate early and long-term results of preoperative radiotherapy plus intraoperative radiotherapy in a homogeneous population of T-3 middle and lower rectal cancer patients submitted to total mesorectal excision. METHODS: A series of 113 patients with middle and lower T3 rectal cancer consecutively submitted to total mesorectal excision at a single surgical unit from 1991 to. 1997 were divided into two groups according to type of neoadjuvant treatment: preoperative radiotherapy (38 Gy) plus intraoperative radiotherapy (10 Gy; n = 69), and no preoperative treatment (total mesorectal excision; n = 44). Standard statistical analyses were used to evaluate early (downstaging, intraoperative factors, hospital morbidity, and mortality rates) and long-term results (recurrence and survival). RESULTS: Overall, 68.2 percent of patients were downstaged by the preoperative regimens (To specimens in 3 cases). Postoperative complications were comparable in the two groups. Five-year, disease-specific survival was 81.4 and 58.1 percent in preoperative radiotherapy plus intraoperative radiotherapy group and total mesorectal excision group, respectively (P = 0.052). Corresponding figures for disease-free survival were 73.1 and 57.2 percent in the two groups, respectively (P = 0.096). The rates of local recurrence at five years were 6.6 and 23.2 percent in preoperative radiotherapy plus intraoperative radiotherapy and total mesorectal excision groups, respectively (P = 0.017). CONCLUSIONS: Preoperative radiotherapy plus intraoperative radiotherapy associated with total mesorectal excision reduce local recurrence rate and improve survival in T-3 rectal cancer compared with total mesorectal excision alone.
引用
收藏
页码:170 / 179
页数:10
相关论文
共 22 条
[1]   Preoperative radiotherapy for resectable rectal cancer -: A meta-analysis [J].
Cammà, C ;
Giunta, M ;
Fiorica, F ;
Pagliaro, L ;
Craxì, A ;
Cottone, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (08) :1008-1015
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers [J].
Delaney, CP ;
Lavery, IC ;
Brenner, A ;
Hammel, J ;
Senagore, AJ ;
Noone, RB ;
Fazio, VW .
ANNALS OF SURGERY, 2002, 236 (02) :203-207
[4]  
Enker WE, 1999, ANN SURG, V230, P544, DOI 10.1097/00000658-199910000-00010
[5]  
Gray R, 2001, LANCET, V358, P1291
[6]   Rectal cancer - The Basingstoke experience of total mesorectal excision, 1978-1997 [J].
Heald, RJ ;
Moran, BJ ;
Ryall, RDH ;
Sexton, R ;
MacFarlane, JK .
ARCHIVES OF SURGERY, 1998, 133 (08) :894-898
[7]   TP53 genotype but not p53 immunohistochemical result predicts response to Preoperative short-term radiotherapy in rectal cancer [J].
Kandioler, D ;
Zwrtek, R ;
Ludwig, C ;
Janschek, E ;
Ploner, M ;
Hofbauer, F ;
Kührer, I ;
Kappel, S ;
Wrba, F ;
Horvath, M ;
Kamer, J ;
Renner, K ;
Bergmann, M ;
Karner-Hanusch, J ;
Pötter, R ;
Jakesz, R ;
Teleky, B ;
Herbst, F .
ANNALS OF SURGERY, 2002, 235 (04) :493-498
[8]   Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer [J].
Kapiteijn, E ;
Marijnen, CAM ;
Nagtegaal, ID ;
Putter, H ;
Steup, WH ;
Wiggers, T ;
Rutten, HJT ;
Pahlman, L ;
Glimelius, B ;
van Krieken, JHJM ;
Leer, JWH ;
van de Velde, CJH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (09) :638-646
[9]   Prognostic value of p53 genetic changes in colorectal cancer [J].
Kressner, U ;
Inganäs, M ;
Byding, S ;
Blikstad, I ;
Påhlman, L ;
Glimelius, B ;
Lindmark, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :593-599
[10]  
MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163